Issue 161 • January 2026

Biopharma’s 2025 M&A boom

M&As in 2025 ended on a strong note, with high activity expected to continue in 2026.

Briefing

FDA appoints Tracy Beth Høeg as fifth CDER head this year

Feature

High-value oncology deals drive China’s licensing boom

Feature

In a Honduran city, biotechs create gene therapy cocktails to fight ageing

Comment

AbbVie-Genmab’s Epkinly sets new standard in second-line FL

In association with

12/18/2025 14:39:12
  • Home | Biopharma’s 2025 M&A boom
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Datwyler
  • Optimal Clinical Trials Company Insight
  • In Depth
  • Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify
  • High-value oncology deals drive China’s drug licensing boom
  • AI takes charge of data, but challenges linger
  • In a Honduran city, biotechs create gene therapy cocktails to fight aging
  • APAC’s rising stars beyond China
  • ASH 2025: AbbVie and Genmab’s Epkinly sets new standard in second-line FL
  • Syngene Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Buyer's Guides
  • Next issue
12/18/2025 00:00:00